the commercial availability of a 14-valent pneumococcal polysaccharide vaccine justifies repeated investigations of the prevalent pneumococcal serotypes to estimate the probable efficacy of vaccination for patients at high risk of pneumococcal infection .
C0305065
pneumococcal polysaccharide vaccine
C0032269
pneumococcal infection